Table 3.
Baseline characteristics of study participants, myocardial
| Total | Male | Female | |
|---|---|---|---|
| n = 174/213 | 54.6% | 45.4% | |
| Age (y) | 61.7 ± 9.3 | 60.4 ± 8.8 | 63.1 ± 9.7 |
| BMI | 27.9 ± 4.4 | 27.3 ± 4.1 | 28.7 ± 4.7 |
| Risk factors | |||
| Positive family history (%) | 44.4 | 39.1 | 50.6 |
| Smoking (%) | 17 | 15.2 | 18.9 |
| Diabetes (%)* | 9.4 | 12.0 | 6.3 |
| Hypercholesterolemia (%) | 39.2 | 35.9 | 43.0 |
| Hypertension (%) | 51.5 | 41.3 | 63.3 |
| Previous cardiac events | |||
| Previous MI (%) | 0.6 | 1.1 | 0 |
| Previous PCI (%) | 2.3 | 3.3 | 1.3 |
| Previous CABG (%) | 0.6 | 1.1 | 0 |
| Duke Clinical Score28 | 40.0 ± 26.1 | 52.6 ± 24.4 | 26.5 ± 20.7 |
| Cardiac medication | |||
| None (%) | 10.2 | 8.9 | 11.7 |
| Statins (%) | 71.9 | 73.3 | 70.1 |
| Anticoagulants (%) | 65.9 | 70.0 | 61.0 |
| Betablocker (%) | 55.7 | 54.4 | 57.1 |
| Calcium antagonist (%) | 16.8 | 21.1 | 11.7 |
| AT2-antagonist or ACE-inhibitor (%) | 32.9 | 31.1 | 35.1 |
| Diuretics (%) | 12.0 | 10.0 | 14.3 |
| Nitrates (%) | 5.4 | 5.6 | 5.2 |
Table summarizes clinical information about available 174 out of 213 patients. Values are presented as% or means (± SD) of 174/213 patients, due to limited availability.
CABG coronary artery bypass grafting; MI myocardial infarction; PCI percutaneous coronary intervention
*Diabetes Type I and Type II